Pharmacologic intervention may be important in reducing brain injury and in improving outcomes in such neonates. Effective strategies in adult models need to be reassessed in the neonate.Īrterial ischemic stroke (AIS) occurs in neonates annually and results in neurologic disabilities such as hemiplegic cerebral palsy, language deficits, developmental delay, epilepsy and behavioral disorders ( 1). The reasons why albumin was not neuroprotective in neonatal stroke compared with adults remain uncertain. increased apparent diffusion coefficient (ADC) reflecting cytotoxic edema. Elevated T2 values suggesting vasogenic edema was seen in albumin compared with saline-treated animals, as was increased water mobility ( i.e. IgG staining at 3 d post-ischemia showed loss of BBB integrity that was significantly reduced after albumin. Hemispheric infarct volumes from MRI were similar in saline and albumin groups (0 h: 39% and 44% d 1: 46% and 55% and d 28:10% and 24%) as were neurobehavioral assessments. IgG staining to assess blood-brain barrier (BBB) integrity and standard histology was obtained on 1, 3, and 28 d.
IFART BRAIN SERIAL
We performed serial neurobehavioral and magnetic resonance imaging (MRI) assessments immediately after tfMCAO (day 0) and on 1, 3, 7, 14, and 28 d. We investigated whether albumin might also be neuroprotective in ischemic brain injury using a transient filament middle cerebral artery occlusion (tfMCAO) model in 10-d-old rat pups treated with 0.25% albumin or saline 1 h after reperfusion.
Human serum albumin therapy confers neurobehavioral and histopathologic neuroprotection in adult stroke models.
0 kommentar(er)
